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Background: This phase I–II trial compared plitidepsin 1-h infusion alone or combined with dacarbazine (DTIC) 1-h infusion as
front-line therapy for advanced melanoma.
Methods: The recommended dose (RD) for plitidepsin/DTIC was defined in the first stage. In the second stage, patients were
randomised to receive single-agent plitidepsin 3.2mgm 2 (n¼ 20) on days 1, 8 and 15 every 4 weeks (q4wk) or plitidepsin
2.4mgm 2 on days 1, 8 and 15 q4wk combined with DTIC 800mgm 2 q4wk (n¼ 38).
Results: The overall response rate with plitidepsin/DTIC was 21.4%; all responders had normal serum lactate dehydrogenase
(LDH) levels and performance statusp1 at baseline. Median progression-free survival (PFS) with plitidepsin/DTIC was 3.3 months
in all patients, and 4.3 months in those with baseline normal LDH. No responses occurred with single-agent plitidepsin and
median PFS was 1.5 months. Both regimens were well tolerated. Haematological abnormalities were more common and
transaminase increases more severe with plitidepsin/DTIC. Treatment-related transaminase increases leading to infusion omission
on day 8 were relatively common. No drug–drug pharmacokinetic interactions were found.
Conclusion: This plitidepsin/DTIC schedule has antitumour activity and manageable toxicity in advanced melanoma. Further
evaluation of plitidepsin 2.4mgm 2 fortnightly and DTIC 800mgm 2 q4wk is recommended.
Dacarbazine (DTIC) was the mainstay of treatment for metastatic
melanoma until the recent approval (in 2011) of the anticytotoxic
T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody ipilimu-
mab and the B-raf protein inhibitor vemurafenib. Responses to
single-agent DTIC were generally short lived and occurred in
6–15% of patients (Falkson et al, 1998; Chapman et al, 1999;
Chiarion Sileni et al, 2001; Avril et al, 2004; Bedikian et al, 2006;
Schadendorf et al, 2006; Patel et al, 2011). Combinations of DTIC
and other cytotoxic drugs increased response rates, but had no
significant effects on survival and were associated with greater
toxicity (Agarwala, 2009; Mouawad et al, 2010). Antitumour
activity was found for DTIC-based chemotherapy combined with
the anti-vascular endothelial growth factor (VEGF) monoclonal
antibody bevacizumab, but these results were preliminary and
required confirmation in randomised trials (Munzone et al, 2007).
Plitidepsin is a cyclic depsipeptide originally isolated from the
Mediterranean tunicate Aplidium albicans and currently produced
by chemical synthesis. It has in vitro activity against a wide range of
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human malignant cell lines, including melanoma. Plitidepsin
triggers apoptosis in vitro and blocks VEGF secretion in different
tumour models. The finding that DTIC increases protein
expression of VEGF and promotes tumour growth and metastasis
in vivo in human melanoma cells (Lev et al, 2003, 2004) suggested
that a combination of plitidepsin and DTIC might have synergistic
antineoplastic effects in metastatic melanoma. Plitidepsin showed
sustained clinical antitumour activity in a melanoma patient in a
phase I study (Anthoney et al, 2000). In a phase II trial, plitidepsin
3-h intravenous (i.v.) infusion administered fortnightly as second-
line therapy induced durable partial response (PR) in 5% of 35
patients with unresectable melanoma resistant to prior DTIC-
based chemotherapy (Eisen et al, 2009).
This open-label clinical trial was divided into two stages. The
first stage was a nonrandomised, dose-finding, phase I study that
evaluated the maximum tolerated dose (MTD) and the recom-
mended dose (RD) of plitidepsin (1-h infusion on days 1, 8,
and 15) combined with DTIC (1-h infusion on day 1) every 4
weeks (q4wk) as front-line treatment for unresectable advanced
melanoma. This weekly plitidepsin schedule was chosen over the
fortnightly schedule to explore whether more frequent drug
infusions would result in less toxicity and an enhanced efficacy
by giving a greater dose density. The DTIC schedule was selected to
accommodate to the weekly plitidepsin schedule and to provide the
patients with a resting week for the recovery of laboratory
parameters. The second stage was a randomised, two-arm, phase II
study that assessed the efficacy of plitidepsin 3.2mgm 2 as 1-h
infusion (on days 1, 8, and 15) q4wk, and of plitidepsin/DTIC
combination at the RD determined in the first stage. The safety
profile and pharmacokinetics (PK) of the study regimens were also
assessed.
MATERIALS AND METHODS
Consenting adult patients were recruited between January 2006
and June 2009 at 12 European centres according to Good Clinical
Practice requirements, the Declaration of Helsinki and local
regulations. Patients were followed up until September 2010.
The protocol was approved by the Clinical Research
Ethics Committee of each centre. A signed written informed
consent was obtained for each patient before any study procedure
was done.
Eligibility criteria. The study enrolled previously untreated adult
patients with advanced malignant melanoma (adjuvant therapy
was allowed if they had recovered from any toxicity); Eastern
Cooperative Oncology Group performance status (ECOG PS)p2;
left ventricular ejection fraction (LVEF) within normal limits; and
adequate organ function: platelet count X100 109 per l;
haemoglobin 49.5 g dl 1; absolute neutrophil count (ANC)
X1.5 109 per l; aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and alkaline phosphatase (AP) p2.5
upper limit of normal (ULN); total bilirubin p1.5ULN;
creatinine clearance X40mlmin 1 or creatinine p1.4mg dl 1;
creatine phosphokinase (CPK) p2.5ULN; and albumin
X2.5 g dl 1.
Patients were excluded if they had received any prior systemic
therapy for metastatic melanoma; if they were relapsing/progres-
sing within 6 months after adjuvant or neoadjuvant therapy for
nonmetastatic melanoma; if they had locoregional melanoma
relapsing or progressing after locoregional drug therapy; if surgery
would result in cure or significant palliation; if treated with any
locoregional or adjuvant investigational product within 30 days
before inclusion, with radiotherapy within 4 weeks before inclusion
(6 weeks in case of extensive radiotherapy); if they had any major
illness incompatible with the protocol; if they were immunocom-
promised; or if they had a history of significant neurological or
psychiatric disorders, or hypersensitivity to any component of the
study drug(s).
Study treatment and dose escalation. Study treatment during the
first stage consisted of plitidepsin (PharmaMar, Colmenar Viejo,
Madrid, Spain) administered as a 1-h i.v. infusion on days 1, 8 and
15, followed by DTIC as a 1-h i.v. infusion on day 1, in cycles of 4
weeks. The starting plitidepsin dose (1.8mgm 2) was 58% of its
single-agent RD, 3.2mgm 2 (Izquierdo et al, 2008). The starting
DTIC dose (800mgm 2) was B60% of the RD intensity
(1000mgm 2 q3wk) for single-agent DTIC when adapted to a
q4wk schedule (Eggermont and Kirkwood, 2004).
Dose escalation during the first stage is summarised in Table 1.
A standard dose-escalation design for conventional cytotoxic
agents was used, with cohorts of 3–6 patients treated at each dose
level. Dose-limiting toxicities (DLTs) were evaluated during cycle 1
and were defined as follows: ANC o0.5 109 per l for 45 days;
grade 3 neutropenia with fever (X38.5 1C), sepsis or other severe
infection; platelet count o25.0 109 per l; any other grade 3/4
nonhaematological adverse event (AE) suspected to be treatment
related (except for nausea/vomiting without an optimal antiemetic
regimen, hypersensitivity reactions and nonclinically relevant
biochemical abnormalities); and any delays in the administration
of a subsequent plitidepsin dose exceeding 2 weeks, or omissions of
the infusions scheduled on days 8 and 15 because of treatment-
related AEs. The MTD was defined as the dose level at which at
least 2 patients had DLTs, and the RD was defined as the highest
dose level at which less than one-third of patients experienced
DLTs.
Table 1. Dose escalation, distribution of patients, treatment cycles and dose-limiting toxicities during the phase I stage
Dose
level
Plitidepsin/DTIC
dose (mgm2)
No. of
patients
treated
No. of cycles
administered
No. of patients with DLTs/no. of
patients evaluable for DLTsa Description of DLTs
1 1.8/800 7 25 1/6 Grade 3 ALT increase
2 2.4/800 (RD) 8 20 1/5 Grade 3 ALT increase
3 3.0/800 8 23 0/6 —
4 2.4/1000 (MTD) 5 8 2/4 Grade 3 ALT increase
Grade 4 febrile neutropenia and
grade 4 pancytopeniab
Abbreviations: ALT¼ alanine aminotransferase; DLT¼dose-limiting toxicity; DTIC¼dacarbazine; MTD¼maximum tolerated dose; RD¼ recommended dose.
aOverall, 21 of 28 patients were considered evaluable for DLTs. Seven patients were not evaluable because of being withdrawn from the study before completing cycle 1 (n¼ 3), the presence of
confounding factors (n¼ 2), a wrong diagnosis of metastatic melanoma (n¼ 1) or having bone marrow sensitivity to DTIC (n¼ 1).
bThis episode of grade 4 pancytopenia consisted of grade 4 leukopenia, grade 4 neutropenia and grade 4 thrombocytopenia.
BRITISH JOURNAL OF CANCER Plitidepsin/DTIC as first-line therapy in melanoma
1452 www.bjcancer.com |DOI:10.1038/bjc.2013.477
During the second stage, eligible patients were randomised
without stratification to receive either single-agent plitidepsin
3.2mgm 2 as 1-h infusion on days 1, 8 and 15 q4wk, or
plitidepsin/DTIC at the RD previously determined in the first
stage. A two-stage Simon design was used in this stage. An interim
analysis was conducted once 17 evaluable patients had been
included in each arm. If two or more responses were observed in
an arm, additional patients were recruited in that arm to a total of
30 evaluable patients. Standard prophylaxis with antihistaminics,
steroids and 5-HT3 antagonists was made compulsory during dose
escalation after some patients had to discontinue treatment because
of severe hypersensitivity reactions (possibly linked to the
Cremophor oil (Duchefa Farma, Haarlem, Nederland) in the
plitidepsin formulation).
Regardless of stage, patients continued receiving treatment as
long as they did not experience disease progression or unacceptable
toxicity and they had recovered from any previous toxicity.
Treatment was interrupted in the event of unacceptable toxicity,
and was resumed at the next lowest dose level upon recovery to
appropriate values. Treatment on day 1 was delayed for a
maximum of 2 weeks to allow recovery from toxicity, but on days
8 and 15 the dose was skipped if the retreatment criteria were not
met. Up to two dose reductions were allowed, if necessary.
Patients were evaluable for safety if they had received at least
one plitidepsin infusion, and for efficacy if they had received at
least two plitidepsin infusions and had undergone disease
assessment over X8 weeks after treatment onset. Patients with
early disease progression who died of progression before response
evaluation or who stopped treatment because of unmanageable
toxicity were also evaluable for efficacy. All toxicities were graded
following the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE, v.3.0). Clinical and/or
radiological assessments of the tumour according to the Response
Evaluation Criteria In Solid Tumours (RECIST, v.1.0) (Therasse
et al, 2000) were done every 8 weeks.
PK analyses. Blood samples (10ml) for PK evaluation were
collected during both stages from a peripheral vein of the arm not
receiving the first study drug infusion at predefined times, ranging
from before infusion onset to up to 168 h after its end. A whole
blood aliquot of 3ml was separated from each sample and stored at
 20 1C for plitidepsin analysis; the remaining sample was
centrifuged at 2500 g for 15min to obtain the plasma fraction,
which was then stored at  20 1C for DTIC analysis. Concentra-
tions of plitidepsin and DTIC were determined using a validated
high-performance liquid chromatography system coupled with
electrospray ionisation tandem mass spectrometry (HPLC-
MS/MS) (Celli et al, 2004). The lower limits of quantification
(LLOQs) were 0.25 ngml 1 for plitidepsin and 4.98 ngml for
DTIC. Complete concentration–time profiles were analysed by
standard noncompartmental methods.
RESULTS
Patient characteristics
Phase I stage. A total of 28 patients were enrolled (Table 2).
Of these, 26 (96%) had metastatic disease and 16 (59%) had X3
sites of disease. At baseline, 27 patients (96%) had an ECOG PS of
0–1. The median lactate dehydrogenase (LDH) level was 0.8
ULN (range, 0.4–3.4ULN).
Phase II stage
Plitidepsin/DTIC: In all, 38 patients were enrolled, all with
metastatic disease (Table 2). Of these, 24 (65%) had X3 sites of
disease. At baseline, 37 patients (97%) had an ECOG PS of 0–1.
The median LDH level was 0.8ULN (range, 0.4–8.2ULN).
Single-agent plitidepsin: A total of 20 patients were included
(Table 2). All had metastatic disease and 16 (80%) hadX3 sites of
disease. Nineteen patients (95%) had an ECOG PS of 0–1.
The median LDH level was 1.7ULN (range, 0.5–3.9ULN).
Treatment exposure
Phase I stage. Dose ranges during escalation are shown in Table 1.
A median of two cycles (range, 1–8 cycles) was administered to
each patient. Dose-limiting toxicity (grade 3 ALT increases)
occurred in one of five patients treated at dose level 2 (plitidepsin
2.4mgm 2 and DTIC 800mgm 2; Table 1). No patients treated
at dose level 3 (plitidepsin 3.0mgm 2 and DTIC 800mgm 2)
had DLTs, but dose omissions on day 8 or 15 occurred in 57% of
cycles administered at this dose level, all because of grade 2/3
transaminase increases. At dose level 4 (plitidepsin 2.4mgm 2
and DTIC 1000mgm 2), DLTs (grade 3 ALT increase, grade 4
pancytopenia and febrile neutropenia) occurred in two of four
evaluable patients. Consequently, this dose level was declared the
MTD for the plitidepsin/DTIC combination, and dose level 2
(plitidepsin 2.4mgm 2 and DTIC 800mgm 2) was considered
the RD.
At the RD, median plitidepsin dose intensity was 1.2mgm 2
per week (range, 0.6–2.0mgm 2 per week) and median relative
plitidepsin dose intensity was 67% (range, 33.1–99.2%). For DTIC,
median dose intensity at the RD was 189.5mgm 2 per week
(range, 151.0–198.9mgm 2 per week) and median relative dose
intensity was 94.8% (range, 75.5–99.5%).
Phase II stage
Plitidepsin/DTIC: A total of 125 cycles were administered, for a
median of 2 cycles (range, 1–11 cycles) per patient. Median
plitidepsin dose intensity was 1.1mgm 2 per week (range,
0.6–1.8mgm 2 per week) and median relative dose intensity was
62% (range, 33.0–100.0%). For DTIC, median dose intensity
was 199.8mgm 2 per week (range, 99.7–203.1mgm 2 per week)
and median relative dose intensity was 99.9% (range, 49.9–101.6%).
Single-agent plitidepsin: A total of 32 cycles were administered,
for a median of 1.5 cycles (range, 1–4 cycles) per patient. Median
plitidepsin dose intensity was 1.6mgm 2 per week (range,
0.8–2.4mgm 2 per week) and median relative dose intensity was
67% (range, 31.7–100.9%).
Efficacy
Phase I stage. In all, 19 treated patients were evaluable for efficacy.
Antitumour activity in this phase consisted of one confirmed PR,
two unconfirmed partial responses (PRu) and four4 disease
stabilisations X3 months.
Phase II stage. Eight patients treated with plitidepsin/DTIC and
four treated with single-agent plitidepsin were not evaluable
because they either withdrew from the study before receiving the
minimum treatment required or did not have disease assessment at
least 8 weeks after treatment onset. Reasons for discontinuation
comprised toxicity (n¼ 8), AEs unrelated to treatment (n¼ 2) or
early disease progression (n¼ 2).
Plitidepsin/DTIC: Of the 28 evaluable patients, 6 showed
objective confirmed responses (1 CR and 5 PRs; ORR¼ 21.4%,
95% CI, 8.3–41.0%; Table 3). The CR occurred in a 21-year-old
female with multiple metastatic lesions (3 in the lungs) who
received a total of 9 cycles. Tumour lesions decreased in size after
cycle 2 and were undetectable after cycle 9, with no subsequent
disease progression at last follow-up (18.7 months after treatment
onset). All patients responding to plitidepsin/DTIC had LDH
p1.1ULN and an ECOG PSp1 at baseline. Median duration of
response was 4.5 months (range, 1.4–16.5þ months). In addition,
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9 patients (32.1%) had disease stabilisation (including 1 PRu) for a
median of 3.9 months (range, 3.1–13.2 months). In the whole
cohort of 28 evaluable patients, median progression-free survival
(PFS) was 3.3 months (95% CI, 1.6–4.6 months) and median OS
was not reached before the database lock (Figure 1). Median PFS
was 4.3 months (95% CI, 2.0–7.9 months) in 20 patients with
baseline LDH p1.1ULN (Table 3).
Single-agent plitidepsin: None of the 16 evaluable patients
achieved objective response. Two (12.5%) had disease stabilisation
(median duration of 2.9 months; range, 2.8–3.0 months; Table 3).
Median PFS for all 16 patients was 1.5 months (95% CI, 0.9–1.9
months; Figure 1) and median OS was 4.1 months (95% CI, 1.5–7.7
months). Median PFS was 1.6 months (95% CI, 1.6–2.8 months) in
3 patients with LDH p1.1ULN (Table 3).
Toxicity profile
Phase I stage (at the RD). All five patients treated at the RD were
evaluable for safety. Most toxicities were grade 1/2. Clinically
relevant toxicities comprised grade 3 fatigue (n¼ 2, concomitant
with grade 4 neutropenic sepsis in one case), grade 3 vomiting,
grade 3 diarrhoea, grade 3 hypersensitivity, grade 3 respiratory
tract infection, grade 3 weakness and grade 4 pancytopenia (n¼ 1).
Transient grade 3 ALT increase occurred in 2 patients.
Table 2. Patient characteristics at baseline
Phase II stage
Phase I stage (n¼28) Plitidepsin (n¼20) Plitidepsin/DTIC (n¼38)
Gender
Male 16 (57%) 10 (50%) 21 (55%)
Female 12 (43%) 10 (50%) 17 (45%)
Median age (years) (range) 48.0 (20–77) 51.5 (36–78) 55.5 (21–76)
ECOG performance status
0 16 (57%) 4 (20%) 21 (55%)
1 11 (39%) 15 (75%) 16 (42%)
2 1 (4%) 1 (5%) 1 (3%)
Median plasma LDH (ULN) (range) 0.8 (0.4–3.4) 1.7 (0.5–3.9) 0.8 (0.4–8.2)
p1.1ULN 20 (71%) 4 (20%) 23 (61%)
41.1ULN 8 (29%) 16 (80%) 15 (39%)
Diseasea
Metastatic 26 (96%) 20 (100%) 38 (100%)
Locally advanced 1 (4%)
Sites of diseasea
Lung 19 (70%) 11 (55%) 25 (68%)
Lymph node 18 (67%) 17 (85%) 27 (73%)
Soft tissue 9 (33%) 5 (25%) 11 (30%)
Liver 8 (30%) 11 (55%) 17 (46%)
Bone 7 (26%) 7 (35%) 6 (16%)
Peritoneum 4 (15%) 4 (20%) 6 (16%)
Pelvis 3 (11%) 1 (5%) 5 (14%)
Skin 2 (7%) 3 (15%) 1 (3%)
Spleen 2 (7%) 4 (20%) 3 (8%)
Kidney 1 (4%) 1 (5%) 5 (14%)
Otherb 5 (19%) 5 (25%) 12 (32%)
Number of sites of diseasea,c
1–2 Sites 11 (41%) 4 (20%) 13 (35%)
X3 Sites 16 (59%) 16 (80%) 24 (65%)
Previous anticancer therapy
Surgery 28 (100%) 20 (100%) 36 (95%)
Radiotherapy 10 (36%) 10 (50%) 7 (18%)
Biological therapy 2 (7%) 1 (5%) 2 (5%)
Chemotherapyd 1 (3%)
Abbreviations: DTIC¼dacarbazine; ECOG¼Eastern Cooperative Oncology Group; LDH¼ lactate dehydrogenase; ULN¼ upper limit of normal.
aOne patient in the phase I stage had hepatic haemangioma instead of melanoma (wrong diagnosis), and has been excluded.
bAdrenal, bladder, breast, central nervous system (CNS), pancreas, parotid gland, pericardial, pleura, stomach and thyroid sites.
cMissing data for one patient treated with plitidepsin/DTIC in the phase II stage.
dIn the neoadjuvant setting.
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Phase II stage. Of the 58 enrolled patients, 56 were treated and
were evaluable for safety. The most common nonhaematological
toxicities were ALT/AST increases, AP increases, fatigue, nausea
and vomiting (in both arms), plus CPK increase with single-agent
plitidepsin, and total bilirubin increase with plitidepsin/DTIC
(Table 4). Severe AEs occurred rarely, mostly reaching grade 3 at
worst, and were properly managed with dose adjustments.
All transaminase increases in both arms were transient. Grade 3
ALT increases were more frequent with plitidepsin/DTIC (28% vs
10% of patients); grade 3 AST increases were rarer and only
occurred with plitidepsin/DTIC (6% of patients). It is noteworthy
that more patients treated with the combination skipped at least
one plitidepsin infusion (77% vs 47%) and more omissions were
because of treatment-related transaminase increases (65% vs 25%)
as compared with plitidepsin alone. Most omissions involved the
plitidepsin infusion on day 8. In contrast, grade 3/4 CPK increase
occurred more frequently with single-agent plitidepsin (15% vs 3%
of patients).
The most common haematological abnormalities were anaemia
and lymphopenia (Table 4). Most were mild or moderate. Severe
abnormalities occurred in 2 patients (10%) treated with single-
agent plitidepsin and 4 (11%) treated with plitidepsin/DTIC.
All other haematological abnormalities were mild and had no
effects on treatment compliance. Notably, no cases of febrile
neutropenia were observed.
Hypersensitivity reactions (n¼ 14) were more frequent with
plitidepsin/DTIC (n¼ 9 patients, 25% vs n¼ 3 patients with single-
agent plitidepsin, 15%) and resulted in the treatment discontinua-
tion of 7 patients (5 vs 2, respectively). Nevertheless, one patient in
each arm had grade 2/3 hypersensitivity reactions but continued
treatment safely without reoccurrence of the events.
Pharmacokinetics. Complete PK data were available from 67
patients (21 during the phase I stage and 46 during the phase II
stage) for plitidepsin, and from 49 patients (17 and 32,
respectively) for DTIC (Table 5). The mean maximum plasma
concentrations (Cmax), area under the curve (AUC) and terminal
half-life (t½) of plitidepsin were similar when the drug was
administered at 3.2mgm 2 as single agent or at 2.4mgm 2
combined with DTIC 800mgm 2. Maximum plitidepsin concen-
trations were typically observed during or immediately before the
end of infusion and then decreased in a multiexponential manner,
with an initial rapid decline followed by a more prolonged
Table 3. Best tumour response and time-related efficacy end points in evaluable patients during the phase II stage
Plitidepsin (n¼16) Plitidepsin/DTIC (n¼28)
n % n %
Complete response 1 3.6
Partial response 5a 17.9
Stable disease 2 12.5 9b 32.1
Progressive disease 14 87.5 13 46.4
Median (months) Range Median (months) Range
Duration of response 4.5 1.4–16.5
Duration of stable disease 2.9 2.8–3.0 3.9 3.1–13.2
Median (months) 95% CI Median (months) 95% CI
All evaluable patients
n 16 28
PFS 1.5 0.9–1.9 3.3 1.6–4.6
Patients with baseline LDH p1.1ULN
n 3 20
PFS 1.6 1.6–2.8 4.3 2.0–7.9
Patients with baseline LDH 41.1ULN
n 13 8
PFS 1.1 0.9–1.9 1.4 1.1–1.6
Abbreviations: CI¼ confidence interval; DTIC¼dacarbazine; LDH¼ lactate dehydrogenase; n¼ number of patients evaluable for efficacy; PFS¼progression-free survival; ULN¼ upper limit of
normal.
aTwo of these responses occurred among the first 17 patients evaluable for efficacy in this arm.
bIncludes one patient treated with plitidepsin/DTIC who had unconfirmed partial response.
(P-value=0.0002)
APL 2.4 mg m–2 / DTIC 800 mg m–2
APL 3.2 mg m–2
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Figure 1. Progression-free survival of patients treated with plitidepsin
alone or with plitidepsin/DTIC during the phase II stage.
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distribution. Both whole blood clearance (CL) and volume of
distribution at steady state (Vss) of plitidepsin were higher when
administered alone. The mean PK parameters observed for DTIC
in this study do not show significant changes between different
plitidepsin dose levels. No interaction between plitidepsin and
DTIC was found.
DISCUSSION
Plitidepsin is a compound with high pleiotropicity, affecting
multiple cell signalling pathways and targets (Munoz-Alonso et al,
2009). Plitidepsin inhibits cell cycle progression, induces apoptosis
and shows antiangiogenic activity. These effects are related to the
induction of early oxidative stress, the activation of Rac1 GTPase
and the inhibition of protein phosphatases, which together cause
sustained activation of two members of the MAPK family: the
serine/threonine kinases JNK and p38 MAPK (Cuadrado et al,
2003). Sensitivity to plitidepsin is inversely correlated with the level
of expression of the Cdk inhibitor p27kip1 in a panel of low-
passage human sarcoma cell lines. Furthermore, the elimination of
p27kip1 in these cells (by siRNA) or in mouse embryo fibroblasts
(MEFs; p27 kip1 knockout) increases their sensitivity to plitidepsin
(Moneo et al, 2007). Phosphorylated JNK has recently been
described as a pharmacodynamic biomarker of plitidepsin in
xenografted tumours as well as in normal surrogate tissues
(Munoz-Alonso et al, 2013).
The first stage of this phase I–II clinical trial found plitidepsin
2.4mgm 2 plus DTIC 800mgm 2 as the RD for plitidepsin 1-h
infusion (days 1, 8 and 15) plus DTIC 1-h infusion (day 1) q4wk
regimen in chemonaive adult patients with advanced malignant
melanoma. Unsurprisingly, transient grade 3 ALT increase was the
most common DLT during dose escalation, which was similar to
the findings of prior plitidepsin studies (Anthoney et al, 2000;
Ciruelos et al, 2002; Faivre et al, 2005; Izquierdo et al, 2008;
Gomez-Roca et al, 2010; Stein et al, 2012). Dose-limiting grade 4
febrile neutropenia and grade 4 pancytopenia occurred in one
patient at the MTD, which was the only level in which DTIC was
administered at 1000mgm 2. Haematological toxicity is more
likely to be linked to DTIC (Chapman et al, 1999) rather than to
plitidepsin, as it is seldom reported in single-agent studies in
patients with nonhaematological tumours (Faivre et al, 2005;
Maroun et al, 2006; Izquierdo et al, 2008).
The second stage of this study explored the efficacy of
plitidepsin alone or in combination with DTIC. The ORR of
21.4% found for patients treated with the combination is within the
ranges (11–31%) reported for DTIC combined with other active
agents in metastatic melanoma, including ipilimumab, for
which an ORR of 15.2% was reported in a recent phase III trial
(Robert et al, 2011). Vemurafenib has resulted in a higher response
rate (55%) in advanced melanoma patients with a BRAF V600E
mutation (Chapman et al, 2012); however, this mutation is only
present in B50% of all melanoma patients. Much lower response
rates have been reported for single-agent DTIC (range, 5–15%),
thus suggesting that the combination of plitidepsin plus DTIC may
Table 4. Worst all-cycle toxicities during the phase II stage
Plitidepsin (n¼20) Plitidepsin/DTIC (n¼36)a
Grade 1/4 Grade 3 Grade 4 Grade 1/4 Grade 3 Grade 4
Nonhaematological
ALT increase 18 (90%) 2 (10%) 33 (92%) 9 (25%) 1 (3%)
Anorexia 2 (10%) 6 (17%)
AP increase 11 (55%) 14 (39%)
AST increase 15 (75%) 25 (69%) 2 (6%)
Constipation 3 (15%) 4 (11%)
CPK increase 7 (35%) 2 (10%) 1 (5%) 7 (19%) 1 (3%)
Creatinine increase 4 (20%) 5 (14%)
Diarrhoea 3 (15%) 7 (19%) 1 (3%)
Electrocardiogram T wave abnormalb 4 (11%)
Fatigue 8 (40%) 1 (5%) 15 (42%) 4 (11%)
Hypersensitivity 3 (15%) 1 (5%) 9 (25%) 3 (8%)
Muscle cramps 2 (10%) 3 (8%) 1 (3%)
Muscle weakness 1 (5%) 1 (5%) 5 (14%) 2 (6%)
Myalgia 4 (20%) 4 (11%)
Nausea 9 (45%) 2 (10%) 25 (69%) 1 (3%)
Total bilirubin increased 5 (25%) 19 (53%)
Vomiting 6 (30%) 1 (5%) 13 (36%) 2 (6%)
Weight decrease 4 (11%)
Haematological
Anaemia 11 (55%) 1 (5%) 23 (64%) 1 (3%)
Leukopenia 9 (25%) 1 (3%)
Lymphopenia 11 (55%) 1 (5%) 19 (53%) 1 (3%)
Neutropenia 10 (28%) 2 (6%)
Thrombocytopenia 5 (25%) 5 (14%) 2 (6%)
Abbreviations: ALT¼ alanine aminotransferase; AP¼ alkaline phosphatase; AST¼ aspartate aminotransferase; CPK¼ creatine phosphokinase; DTIC¼dacarbazine; n¼ number of patients
evaluable for safety. Data shown are number (%) of patients. Only toxicities found in X10% of patients with either treatment are included. Haematological and laboratory abnormalities are
shown regardless of their relationship to treatment.
aTwo patients enrolled into this cohort were withdrawn before receiving the first infusion and thus were not evaluable for safety.
bThese comprised grade 2 electrocardiogram T wave inversion (n¼ 2), grade 2 electrocardiogram T wave abnormal, and grade 1 electrocardiogram T wave amplitude decreased (n¼ 1 each).
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indeed have had a synergistic antitumour effect. Moreover, as the
DTIC dose given (800mgm 2 q4wk) is lower than the one
usually administered to patients with metastatic melanoma
(Mouawad et al, 2010), this might have also resulted in a much
lower haematological toxicity compared with full-dose DTIC.
The finding that all six responders to plitidepsin/DTIC in the
second study stage had serum LDH levels p1.1ULN and an
ECOG PS p1 at baseline is intriguing, but may reflect an
imbalance for known prognostic factors in both arms, and that
these patients were in better condition or had better prognosis.
No responses occurred with single-agent plitidepsin. This lack
of response may be partly related to the patients’ poor prognosis at
baseline because of lack of stratification. Known prognostic factors,
such as high serum LDH (an independent and highly significant
predictor of survival in advanced melanoma) (Balch et al, 2003;
Bedikian et al, 2008; Neuman et al, 2008), ECOG PS or the
presence of visceral metastases, were not taken into account owing
to the small number of patients planned to be included in this
small phase I–II study. During the second stage, more patients in
the combination arm had baseline LDH p1.1ULN (61% vs
20%) and ECOG PS¼ 0 (55% vs 20%), and fewer had X3 sites of
disease at baseline (65% vs 80%). These differences suggest, in a
post hoc analysis, that a better prognosis at baseline favoured
patients included in the combination arm, and might have
contributed towards the different response to treatment achieved
in each arm.
Small differences were found between the safety profiles of
single-agent plitidepsin and plitidepsin/DTIC. Nevertheless, both
regimens were generally well tolerated and showed manageable
toxicity. The overall toxicity profile of single-agent plitidepsin
agrees with that previously reported for this same schedule (Ferme
et al, 2008; Izquierdo et al, 2008). The addition of DTIC might
have contributed towards the slightly greater incidence of nausea,
fatigue, vomiting and transaminase increases found with the
combination, although these toxicities are also frequently reported
with DTIC monotherapy (Patel et al, 2011). The hypersensitivity
reactions related to plitidepsin/DTIC were more common and
more severe than expected, based on the toxicity profiles reported
for either drug alone (Chapman et al, 1999; Ferme et al, 2008;
Izquierdo et al, 2008; Patel et al, 2011); the reasons underlying this
finding remain to be elucidated.
Biochemical abnormalities occurred at similar frequencies in
both regimens, although transaminase increases were slightly more
frequent with the combination. Most patients (77%) treated with
the combination skipped at least one plitidepsin infusion, generally
because of treatment-related ALT or AST increases and involving
the Day 8 infusion. Skipping the Day 8 infusion generally resulted
in resolution and did not compromise further dosing. Thus, a
fortnightly schedule might be more convenient for plitidepsin when
combined with DTIC in the treatment of metastatic melanoma.
As expected, haematological abnormalities were more frequent
with plitidepsin/DTIC than with plitidepsin alone. Neutropenia
only occurred with the combination. However, only 11% of
patients treated with the combination had severe haematological
abnormalities resulting in treatment delay or dose reduction.
Severe bone marrow depletion has been reported as a frequent
reason for discontinuation in DTIC-based chemotherapies
(Jungnelius et al, 1998; Agarwala et al, 1999; Chapman et al,
1999; Chiarion Sileni et al, 2001; Jelic et al, 2002). Overall, these
results suggest that addition of plitidepsin may improve the
antitumour efficacy of DTIC in metastatic melanoma while not
increasing its known haematological toxicity.
The overall whole blood PK parameters obtained for plitidepsin
alone or combined with DTIC were similar to those found in a
previous phase I study (Izquierdo et al, 2008). The profile was
characterised by a long half-life, low clearance and a high volume
of distribution. Drug levels peaked during or immediately before
the end of infusion, and then decreased in a multiexponential
manner. The mean plasma PK parameters found for DTIC were
also similar to those reported in previous studies (Buesa and
Urrechaga, 1991). Therefore, no drug–drug PK interactions were
apparent.
Table 5. Pharmacokinetic parameters of plitidepsin and DTIC in cycle 1
Plitidepsin/DTIC dose level (mgm2) n Cmax (ngml
 1) AUC (hngml 1) t½ (h) CL (l h 1) Vss (l)
Plitidepsin
Phase I stage
1.8/800 6 41.7 (25.6–50.4) 540 (240–824) 42.7 (32.2–56.5) 7.1 (3.8–12.1) 261 (175–401)
2.4/800 (RD) 6 42.4 (30.0–49.8) 508 (262–727) 39.5 (16.3–53.6) 10.4 (7.6–17.0) 408 (163–590)
3.0/800 7 38.1 (24.6–49.0) 323 (212–523) 38.8 (15.4–69.1) 19.0 (11.9–28.3) 750 (316–1920)
2.4/1000 (MTD) 2 36.0 (35.5–36.4) 277 (184–369) 16.1 (15.1–17.0) 16.7 (11.1–22.2) 299 (245–353)
Phase II stage
3.2 17 38.3 (16.1–48.4) 444 (205–848) 45.1 (14.2–131) 15.4 (7.5–24.5) 652 (198–1380)
2.4/800 29 40.3 (26.2–50.2) 425 (215–1130) 43.0 (13.7–85.5) 12.0 (4.0–24.9) 456 (158–826)
DTIC
Phase I stage
1.8/800 5 19.9 (15.1–23.9) 46.0 (30.3–69.8) 1.3 (0.7–2.4) 35.2 (22.4–47.8) 50.6 (37.1–66.1)
2.4/800 (RD) 7 18.2 (5.0–24.4) 42.3 (24.5–66.8) 1.4 (0.5–1.9) 41.8 (22.3–68.6) 76.7 (28.4–185)
3.0/800 4 16.1 (4.2–22.9) 48.2 (14.8–84.9) 2.5 (2.2–2.9) 41.3 (18.9–86.6) 94.8 (63.7–156)
2.4/1000 (MTD) 1 4.6 ( ) 15.7 ( ) 3.5 ( ) 114 ( ) 385 ( )
Phase II stage
2.4/800 32 15.4 (4.3–22.6) 38.3 (13.6–60.8) 2.6 (1.2–6.7) 42.8 (22–124) 96.2 (45.8–249)
Abbreviations: AUC¼ area under the concentration–time curve from time zero to infinity; CL¼ total body clearance; Cmax¼maximum plasma concentration; DTIC¼dacarbazine;
MTD¼maximum tolerated dose; RD¼ recommended dose; t½¼ terminal half-life; Vss¼ volume of distribution at steady state. Values are expressed as mean (range).
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This study was initiated before the availability of BRAF
inhibitors and targeted immune therapies. It is unclear now how
to assess a precise role for the plitidepsin/DTIC combination in the
rapidly changing treatment options for advanced melanoma.
Patient selection by BRAF status has led to high response rates
but not durable responses in BRAF V600E-mutated melanoma and
overall survival is improved with treatment with ipilimumab.
Despite these improvements, most patients with advanced
melanoma will ultimately progress and die of their disease; thus,
new treatment options are still needed. The results of this study are
promising, taking into account the novel mechanism of action of
plitidepsin, which allows the drug to act synergistically with DTIC
without adding harmful toxicity.
In conclusion, this phase I–II study shows plitidepsin
2.4mgm 2 1-h infusion (days 1, 8 and 15) plus DTIC
800mgm 2 1-h infusion (day 1) q4wk as an active, well-tolerated,
first-line chemotherapy against metastatic melanoma. Further
evaluation of plitidepsin/DTIC as a fortnightly schedule might be
warranted in non-BRAF-mutated advanced melanoma patients.
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